GHK-Cu: mechanism, evidence, and why this tripeptide spans three research clusters.
GHK-Cu is the tripeptide glycine-histidine-lysine bound to copper(II). It was isolated from human plasma in 1973 — decades before the research-chemical market existed — and its role in wound repair signalling, collagen synthesis, and copper transport has been studied continuously since. The result is a compound with genuinely solid upstream biology, some real topical human data, and an injectable-use evidence base that remains largely in rodent and in vitro territory.
- Isolated by Pickart from human plasma in 1973 (J Invest Dermatol). Not synthetic — it corresponds to a physiologically occurring tripeptide.
- Molecular formula C14H24CuN6O4; MW ~403 Da for the copper complex. Histidine imidazole ring coordinates copper(II) with femtomolar-range Kd.
- In vitro: stimulates type I and III collagen synthesis, glycosaminoglycans, decorin, and fibronectin in fibroblasts.
- Rodent models: accelerated wound healing, some angiogenic effects, anti-inflammatory cytokine modulation.
- Human evidence: topical clinical trials show modest improvements in skin density and fine lines. No published RCT for injectable/systemic GHK-Cu in musculoskeletal indications.
- Hub spoke: GHK-Cu is cross-referenced from the Muscle, Skin, and Longevity clusters — same molecule, three application stories.
Origin: Pickart's 1973 isolation
Loren Pickart first isolated GHK from human plasma in 1973, reporting in the Journal of Investigative Dermatology that the tripeptide stimulated rat liver ornithine decarboxylase — an enzyme involved in cell proliferation and polyamine synthesis. This was early evidence that a small plasma peptide could act as a biological regulatory signal. Pickart spent subsequent decades characterising GHK-Cu's role in wound repair and tissue remodelling; his 2018 review in Rejuvenation Research (with Margolina) synthesises gene-expression microarray data suggesting GHK-Cu modulates the expression of hundreds of human genes associated with wound healing, anti-aging, and tumour suppression.
The copper(II) binding is not incidental. GHK's histidine residue coordinates copper through its imidazole ring in a geometry that distinguishes GHK-Cu from simple copper chelation. The copper-bound form has demonstrably different activity from free GHK in key assays including cell migration and collagen synthesis. This means that a vendor COA confirming "GHK" purity without confirming copper loading is not providing complete product characterisation.
Structural chemistry
The free tripeptide Gly-His-Lys (GHK) has a molecular weight of approximately 340.4 Da. The copper(II) complex, GHK-Cu, adds approximately 63.5 Da, giving the complex approximately 403 Da. GHK binds copper with a dissociation constant reported in the femtomolar range in some assay systems — making it one of the highest-affinity small-peptide copper binders characterised in the human proteome. This affinity is the basis for proposals that GHK serves as a physiological copper transporter in plasma, delivering copper to enzymatic systems that require it (lysyl oxidase for collagen crosslinking; superoxide dismutase for antioxidant function).
The short chain length has practical implications. At ~403 Da, GHK-Cu is substantially smaller than longer cosmeceutical peptides like Matrixyl (palmitoyl pentapeptide-4, ~803 Da) and is expected to penetrate stratum corneum more readily in topical formulations. For injectable applications, the small size makes it a substrate for circulating dipeptidyl peptidases, and plasma half-life after injection in humans is not established by any published pharmacokinetic study.
Proposed mechanisms
Collagen and extracellular matrix synthesis. Siméon et al. (2000, J Invest Dermatol) reported that GHK-Cu increased type I and III collagen, decorin, and glycosaminoglycan production in cultured human fibroblasts and in a skin equivalent (three-dimensional culture) model. This is the foundational in vitro data for both the skincare application and the joint/tendon speculative story: if GHK-Cu upregulates collagen synthesis in fibroblasts, the same logic that supports its use in skin theoretically applies to tendon, ligament, and cartilage fibroblasts. The extrapolation is biologically plausible; it is not validated by controlled connective-tissue studies.
Wound healing and angiogenesis. Pollard et al. (2005, J Biomater Sci Polym Ed) reported accelerated wound healing in a rat model with GHK-Cu incorporated into a scaffold. Angiogenic effects have been proposed through VEGF pathway interaction, though the mechanistic chain is less well characterised than BPC-157's VEGFR2 work. Buffoni et al. (1992) contributed early wound-healing rodent data.
Anti-inflammatory effects. Cell-culture models show GHK-Cu down-regulates inflammatory cytokines including IL-6 and TNF-α. This anti-inflammatory component is relevant to joint-tissue applications: joint pain and cartilage degradation have inflammatory drivers where an anti-inflammatory signal could theoretically be beneficial. The gap is the same: in vitro cytokine modulation does not validate a clinical anti-inflammatory effect.
Broad gene-expression regulatory activity. Pickart and Margolina (2018) present microarray data suggesting GHK-Cu influences expression of hundreds of human genes. The breadth of this claim requires proportionate caution: gene-expression changes in cell culture do not automatically translate to functional benefits in complex tissues in vivo, and the dataset comes from a single investigator's program without independent comprehensive replication.
The topical evidence: where the human data actually lives
The strongest human evidence for GHK-Cu is in topical dermatology. Gorouhi and Maibach (2009), in a systematic review of cosmeceutical peptides in Skin Pharmacology and Physiology, found GHK-Cu among the better-characterised topical peptides with some clinical trial support — more evidence than most compounds in this cluster can claim. Leyden et al. (2019) reported a clinical trial in which a GHK-Cu-containing formulation improved measures of fine lines and skin density over 12 weeks; this is a sponsored cosmetic trial but it represents actual human data.
The topical application story is developed in detail in our Skin & Dermatological pillar. The GHK-Cu topical copper peptide page covers formulation concentrations, penetration data, and the direct comparison with Matrixyl. The anti-aging framing is treated in spoke 3.4 of the Longevity cluster — see our GHK-Cu anti-aging overview for that angle.
The injectable evidence gap for musculoskeletal use
Injectable/systemic GHK-Cu for tendon, muscle, or joint indications is an extrapolation from the fibroblast and wound-healing data. The key unknowns:
- Plasma pharmacokinetics. No published human PK study establishes half-life, distribution volume, or clearance after subcutaneous injection. GHK's tripeptide nature makes it a substrate for serum peptidases; rapid degradation is plausible.
- Target-tissue access. Dermis is accessible topically with modest penetration. Tendon, articular cartilage, and skeletal muscle are avascular or poorly vascularised — GHK-Cu's ability to reach these tissues after systemic injection at therapeutically relevant concentrations is unknown.
- Dose-response.** Cell-culture experiments use nanomolar to low-micromolar concentrations. What subcutaneous dose produces those concentrations in target tissues in humans is not established.
This gap does not make injectable GHK-Cu inert — it means the evidence base does not allow clinical conclusions about the injectable route for musculoskeletal indications. The compound is biologically active; the question is whether the route, dose, and target tissue are aligned in research settings the way they are in fibroblast culture dishes.
Researchers interested in GHK-Cu for joint or tendon contexts should read it alongside the collagen peptide evidence on our peptides for joint pain page — collagen peptides have Phase III-equivalent human trial data for joint outcomes that GHK-Cu injectable does not have. The peptides for rotator cuff page applies the evidence to a specific anatomical target and is comparably honest about what injects vs what is in vitro.
GHK-Cu vs Matrixyl: the topical comparison
GHK-Cu and Matrixyl (palmitoyl pentapeptide-4, also known as Pal-KTTKS) are the two most evidence-backed cosmeceutical peptides. Understanding how they compare is relevant for researchers who encountered GHK-Cu through skincare and are asking whether injectable GHK-Cu is categorically different.
| Property | GHK-Cu | Matrixyl (Pal-KTTKS) |
|---|---|---|
| Structure | Tripeptide + copper(II) | Palmitoyl pentapeptide, no metal |
| MW | ~403 Da (copper complex) | ~803 Da |
| Primary proposed mechanism | Collagen synthesis, copper transport, wound signalling | Collagen I/III and fibronectin stimulation via TGF-β pathway |
| Human topical RCT data | Modest; some clinical trials published | Modest; similar level of evidence |
| Injectable research | Rodent wound models; in vitro fibroblast | Essentially none |
| Regulatory status | Cosmetic ingredient globally; no drug approval | Cosmetic ingredient globally; no drug approval |
Both compounds have similar evidence levels for topical use. Neither has adequate human data for injectable systemic musculoskeletal applications. For a comparison that includes Argireline and copper peptides for hair growth, see the Skin cluster spoke articles.
Vendor considerations: copper loading
GHK-Cu for research is supplied as a lyophilized powder — the copper complex itself, not free GHK. A key COA item that is often absent: confirmation that copper is present in the correct stoichiometry. A vendor selling "GHK-Cu" without ICP-MS or mass-spec confirmation of the copper-bound complex may be selling free GHK, which has different activity in cell-migration and collagen-synthesis assays. The copper content should be verifiable in the COA.
Research vials are typically 50–200 mg, reflecting the lower per-dose mass relative to BPC-157 or TB-500 vials. Reconstitution uses sterile water or bacteriostatic water. Our general reconstitution guide covers BAC water preparation for small peptides of this type.